Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

By A. Onitilo, J. Engel, R. Greenlee, B. Mukesh. Clinical Medicine Research, 2009

1,066 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/1895c6115a8e616ed324a996ce59389b45437682

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. H. Salehiniya
2. D. Garfield
3. Zohre Momenimovahed
4. Jianhua Wang
5. E. Keller
6. Y. Mao
7. K. Shen
8. A. Jemal

Citations in the corpus

• US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. (2014, methodology): “Using tumor subtype definitions based on joint ER/PR/ HER2 status (6,14,21), tumors were classified into four mutually exclusive categories: HR+/HER2−; ER−/PR−/HER2− (triple negative); HR+/HER2+; and HR−/HER2+.”
• Epidemiological characteristics of and risk factors for breast cancer in the world (2019, background): “of invasive breast cancer, which is used to provide therapeutic approaches and to predict clinical outcomes.(11) The”
• Stroma Cells in Tumor Microenvironment and Breast Cancer (2012, positive): “five subtypes (luminal A, luminal B, HER2-positive, basallike, and normal-like) according to different gene expressions [23], among different subtypes or in the same subtype, patients have different prognosis and different lengths of survival [24, 25], which may contribute to heterogeneous stroma, a”